LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRXBiotechnology
-$0.39 today
- Market cap
- $1.30B
- Beta
- 0.71
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.39
Volume 0.36M
Average 0.23M
LBRX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
LB Pharmaceuticals Inc Common StockNASDAQ: LBRX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows 401.4% year over year
Q1 FY2026 research & development of $14.65M rose 401.4% year over year. Sequentially, it rose 72.6% from the prior quarter. Over 3 fiscal years it compounded at +131.7% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 16.74M USD
- Year-over-year change
- -67.3%
- 3-year CAGR
- +131.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.74M | -67.3% |
| FY2024 | 2024-12-31 | 51.17M | +552.3% |
| FY2023 | 2023-12-31 | 7.85M | +482.8% |
| FY2022 | 2022-12-31 | 1.35M | — |
Research & Development vs competitors
How LBRX compares with its peers on the latest reported figures
- LBRX's LTM Mar 2026 research & development of $28.47M is the lowest of the 10 companies compared; the peer median is $169.81M.
- Over three fiscal years its annual growth of +131.7% compares with a peer median of +23.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $5.27B | +80515.8% | -26.7% | — | |
| LTM Jun 2026 | $400.72M | -3.9% | +5.3% | 11118.8% | |
| LTM Sep 2026 | $319.46M | -7.3% | -3.1% | 26.6% | |
| LTM Mar 2026 | $171.97M | +136.8% | +73.1% | — | |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $169.81M | +60.3% | +48.2% | — |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $162.51M | -21.6% | +18.9% | — |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $107.93M | +58.7% | +118.3% | 539.7% |
| LTM Mar 2026 | $55.94M | +19.0% | +24.4% | — | |
| LTM Mar 2026 | $43.27M | +26.5% | +23.7% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $28.47M | — | +131.7% | — |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LBRX) | $169.81M | +26.5% | +23.7% | 539.7% | |
Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 1.35M | 7.85M | 51.17M | 16.74M |
| Selling, General & Admin | 1.46M | 3.53M | 13.66M | 13.66M |
| Operating Expenses | 2.81M | 11.38M | 64.83M | 30.4M |
| Depreciation & Amortization | 2K | 4K | 91K | 321K |
| EBITDA | (12.19M) | (1.45M) | (63.01M) | (24.88M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (2.81M) | (11.38M) | (64.83M) | (30.4M) |
| Operating Margin | — | — | — | — |
| Interest Income | 73K | 811K | 1.72M | 3.92M |
| Interest Expense | 2.15M | 4.83M | 0 | 0 |
| Other Income / Expenses | (11.54M) | 5.1M | 1.73M | 5.2M |
| Income Before Tax | (14.35M) | (6.27M) | (63.1M) | (25.2M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 1K | 1K | 1K | 1K |
| Net Income | (14.35M) | (6.28M) | (63.1M) | (25.21M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (4.05) | (1.77) | (17.83) | (1.00) |
| EPS (Diluted) | (4.05) | (1.77) | (17.83) | (1.00) |
| Weighted Avg Shares | 3.54M | 3.54M | 3.54M | 25.3M |
| Weighted Avg Shares (Diluted) | 3.54M | 3.54M | 3.54M | 25.3M |
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
Intrinsic Alpha fair value
Locked
Current Price
$40.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.